FAIR VALUE MEASUREMENTS |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2024 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fair Value Measurements [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| FAIR VALUE MEASUREMENTS |
NOTE
12 - FAIR VALUE MEASUREMENTS:
Financial
instruments measured at fair value on a recurring basis
The
Company’s assets and liabilities that are measured at fair value as of December 31, 2024, and December 31, 2023, are classified
in the tables below in one of the three categories described in “Note 2 – Fair value measurement” above:
The
following is a roll forward of the fair value of liabilities classified under Level 3:
ELOC
Agreement
As
the ELOC is in substance a purchased call option over the Company’s own shares at a price described in Note 3(d), the fair value
of this agreement was generally approximately zero until the Company sold shares under the ELOC Agreement. Once the Company sold shares
under the agreement, the difference between cash raised (net of transaction costs) and the closing price of the Company’s ordinary
shares as of the date of their issuance was recognized as financing income or expenses. As of December 31, 2024 the ELOC’s fair
value is zero.
Fair
value gain and losses arising from the ELOC Agreement are measured with reference to the spot price of the Company’s shares sold,
less consideration receivable from the ELOC Investor.
Warrant
to purchase preferred shares
The
fair value of Silexion’s warrant to purchase preferred shares as of December 31, 2023 was estimated using a hybrid model in order
to reflect two scenarios: (1) an IPO event (including de-SPAC transaction) involving Silexion and (2) other liquidation events involving
Silexion.
The
IPO scenario (including de-SPAC transaction) involving Silexion was based on management’s estimation regarding the expected value
of the Company’s entire equity at the IPO event (including de-SPAC transaction). Valuation under this scenario was assessed using
the probability-weighted expected return method (PWERM).
The
valuation under the ‘other liquidation events’ scenario was assessed using an option pricing model (OPM) by implementing a
Monte Carlo simulation, which treats the financial instruments in Silexion’s equity as contingent claims whose future payoff depends
on Silexion’s future equity value. Silexion’s entire equity value in 2023 was calculated based, among others, on the financing
round closest to the valuation date.
All
warrants to purchase Silexion preferred shares were automatically exercised on a cashless basis immediately prior to the Closing; see
Note 1(d).
Promissory
Notes
In
measuring the fair value of the Company’s Promissory Notes in 2024, a discount rate of 11.63%-13.85%
was used, based on a B- rated US dollar zero-coupon discount curve, plus a credit spread of 6.67%.
The expected timing of conversion or repayment of the notes was determined using the Company’s forecasts.
Warrants
over ordinary shares
A
Black-Scholes-Merton model with Level 3 inputs was used to calculate the Company’s warrants’ fair value. Inherent in a Black-Scholes-Merton
model are assumptions related to expected life (term), expected stock price, volatility, risk-free interest rate and dividend yield. The
Company estimates the volatility of its warrants based on implied volatility from the Company’s traded warrants and from historical
volatility of selected peer companies’ Class A ordinary shares that matches the expected remaining life of the warrants. The risk-free
interest rate is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected remaining
life of the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. The dividend
rate is based on the historical rate, which the Company anticipates will remain at zero.
The
following table provides quantitative information regarding Level 3 fair value measurement inputs of the warrants:
Financial
instruments not measured at fair value
The
carrying amounts of cash and cash equivalents, restricted cash, receivables, trade payables and other liabilities approximate their fair
value due to the short-term maturity of such instruments. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||